Trial Profile
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms ZACTIMA 58; ZETA
- Sponsors AstraZeneca; Sanofi Genzyme
- 22 Sep 2023 Planned End Date changed from 29 Dec 2023 to 28 Jun 2024.
- 03 Oct 2022 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
- 05 May 2022 The trial has been completed in Hungary, according to European Clinical Trials Database record.